Jagsonpal Pharma

Which are the latest news on Jagsonpal Pharma?

Why is Jagsonpal Pharmaceuticals Ltd falling/rising?

As of N/A, Jagsonpal Pharmaceuticals Ltd's stock price is rising to 231.00, reflecting a 3.87% increase. This performance outpaces the benchmark Sensex, with significant gains over various periods, indicating strong market outperformance.

As of N/A, Jagsonpal Pharmaceuticals Ltd's stock price is rising, currently at 231.00, reflecting an increase of 8.6, or 3.87%. This upward movement can be attributed to the stock's strong performance compared to the benchmark Sensex over various periods. Over the past week, the stock has risen by 10.63%, while the Sensex has decreased by 0.79%. Additionally, the stock has shown a year-to-date increase of 19.60%, contrasting sharply with the Sensex's decline of 10.58%. <BR><BR>The stock's performance over longer periods also highlights its strength, with a 3-year increase of 54.12% compared to the Sensex's 20.99%, and an impressive 5-year growth of 281.19% against the Sensex's 45.68%. These figures indicate that Jagsonpal Pharmaceuticals Ltd is outperforming the market, contributing to the rise in its stock price.

Should I buy, sell or hold Jagsonpal Pharmaceuticals Ltd?

How big is Jagsonpal Pharma?

As of 10th June, Jagsonpal Pharmaceuticals Ltd has a market capitalization of 1,327.00 Cr, with recent net sales of 287.23 Cr and a net profit of 43.08 Cr.

As of 10th June, Jagsonpal Pharmaceuticals Ltd has a market capitalization of 1,327.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest 4 quarters, the company reported Net Sales of 287.23 Cr and a Net Profit of 43.08 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 239.95 Cr and Total Assets of 278.26 Cr.

Who are in the management team of Jagsonpal Pharma?

The management team of Jagsonpal Pharma includes Manish Gupta (Managing Director), Harsha Raghavan (Chairman & Non-Executive Director), and several Independent Directors: Debasis Bikash Nandy, Radhika Dudhat, and Pallavi Dinodia, along with Prithipal Singh Kochhar (Non-Executive Director) and Abhishek Joshi (Company Secretary & Compliance Officer).

The management team of Jagsonpal Pharma includes the following members:<BR><BR>1. **Manish Gupta** - Managing Director<BR>2. **Harsha Raghavan** - Chairman & Non-Executive Director<BR>3. **Debasis Bikash Nandy** - Independent Director<BR>4. **Radhika Dudhat** - Independent Director<BR>5. **Pallavi Dinodia** - Independent Director<BR>6. **Prithipal Singh Kochhar** - Non-Executive Director<BR>7. **Abhishek Joshi** - Company Secretary & Compliance Officer<BR><BR>If you need more details about any specific member or their roles, feel free to ask!

Who are the peers of the Jagsonpal Pharma?

Jagsonpal Pharma's peers include Amrutanjan Health, Ind-Swift Labs, Shukra Pharma, and others. Fredun Pharma leads in 1-year returns at 211.49%, while Jagsonpal Pharma has a return of -13.93%.

Peers: The peers of Jagsonpal Pharma are Amrutanjan Healt, Ind-Swift Labs., Shukra Pharma., Syncom Formul., Lincoln Pharma., Fredun Pharma, Bajaj Healthcare, Fermenta Biotec., Accent Microcell, and Beta Drugs Ltd.<BR><BR>Quality Snapshot: Excellent management risk is observed at Amrutanjan Healt, while Average management risk is found at Shukra Pharma., Syncom Formul., Lincoln Pharma., Fredun Pharma, Bajaj Healthcare, Fermenta Biotec., Accent Microcell, and Beta Drugs Ltd, and the rest. Growth is Excellent at Shukra Pharma and Fredun Pharma, while Below Average growth is seen at Amrutanjan Healt, Ind-Swift Labs., Jagsonpal Pharma, Syncom Formul., Lincoln Pharma., Bajaj Healthcare, Fermenta Biotec., and the rest. Excellent capital structure is noted at Amrutanjan Healt, Shukra Pharma, Jagsonpal Pharma, Syncom Formul., Lincoln Pharma., and Accent Microcell, while Below Average capital structure is found at Ind-Swift Labs., Fredun Pharma, Bajaj Healthcare, Fermenta Biotec., and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Fredun Pharma at 211.49%, while the peer with the lowest is Amrutanjan Healt at -19.65%. Jagsonpal Pharma's own 1-year return is -13.93%, which is better than Amrutanjan Healt but worse than Fredun Pharma. Additionally, Bajaj Healthcare and Fermenta Biotec. have negative six-month returns.

What does Jagsonpal Pharma do?

Jagsonpal Pharmaceuticals Ltd manufactures and markets bulk drugs and pharmaceuticals, categorized as a Micro Cap company with a market cap of INR 1,327 Cr. As of March 2026, it reported net sales of 64 Cr and a net profit of 9 Cr.

Overview: <BR>Jagsonpal Pharmaceuticals Ltd is engaged in the manufacture and marketing of bulk drugs and pharmaceuticals, operating within the Pharmaceuticals & Biotechnology industry and categorized as a Micro Cap company.<BR><BR>History: <BR>Incorporated in August 1978, Jagsonpal Pharmaceuticals has maintained its status as a manufacturer and marketer of pharmaceuticals. The latest quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 64 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 9 Cr (Quarterly Results - Mar 2026) <BR>Market Cap: INR 1,327 Cr (Micro Cap) <BR><BR>Key Metrics: <BR>P/E: 30.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 1.26% <BR>Debt Equity: -0.59 <BR>Return on Equity: 17.66% <BR>Price to Book: 5.24 <BR><BR>Contact Details: <BR>Address: T-210 J, Shahpur Jat New Delhi New Delhi : 110049 <BR>Tel: 91-011-46181100/46109900 <BR>Email: nandita.singh@jagsonpal.com <BR>Website: http://www.jagsonpal.com

Are Jagsonpal Pharmaceuticals Ltd latest results good or bad?

Jagsonpal Pharmaceuticals Ltd's latest results show a year-on-year profit increase of 33.13% and revenue growth of 9.63%, but a concerning quarter-on-quarter decline in both profit and revenue, along with reduced operating margins, suggests potential challenges ahead. Investors should be cautious due to these mixed signals.

Jagsonpal Pharmaceuticals Ltd's latest results present a mixed picture. On one hand, the company reported a net profit of ₹8.76 crores for Q4 FY26, which is a significant year-on-year increase of 33.13%. Additionally, revenue for the same quarter was ₹64.20 crores, reflecting a 9.63% growth compared to the previous year.<BR><BR>However, when looking at the quarter-on-quarter performance, the results are concerning. Both net profit and revenue saw declines of 20.00% and 11.99%, respectively, compared to Q3 FY26. This marks the fourth consecutive quarter of either declining or stagnant revenues, indicating potential challenges in demand or market share.<BR><BR>Furthermore, the operating margin decreased significantly from 22.32% in Q3 FY26 to 17.38% in Q4 FY26, raising questions about the company's operational efficiency and cost management. <BR><BR>In summary, while the year-on-year growth figures are positive, the sequential declines and margin compression suggest underlying issues that could impact the company's future performance. Investors may want to approach with caution given these mixed signals.

Is Jagsonpal Pharma technically bullish or bearish?

As of December 1, 2025, Jagsonpal Pharma's trend is mildly bearish due to bearish momentum indicated by the weekly MACD and KST, despite some mixed signals from Bollinger Bands and Dow Theory.

As of 1 December 2025, the technical trend for Jagsonpal Pharma has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by the weekly MACD and KST both indicating bearish momentum, while the daily moving averages also reflect a mildly bearish outlook. The weekly Bollinger Bands suggest a mildly bearish trend, contrasting with the monthly Bollinger Bands which are bullish. The Dow Theory shows a mildly bullish signal on the weekly timeframe, but overall, the lack of strong bullish signals in the MACD and RSI, combined with the mixed indicators, supports the mildly bearish stance.

How has been the historical performance of Jagsonpal Pharma?

Jagsonpal Pharma has shown significant financial growth, with net sales increasing from 158.57 crore in Mar'20 to 268.72 crore in Mar'25, and profit after tax rising from 7.22 crore to 55.36 crore during the same period. The company has also improved its operating profit margin from 5.38% to 19.0%.

Answer:<BR>The historical performance of Jagsonpal Pharma shows a significant growth trajectory in its financial metrics over the years.<BR><BR>Breakdown:<BR>Jagsonpal Pharma's net sales increased from 158.57 crore in Mar'20 to 268.72 crore in Mar'25, reflecting a strong upward trend. Total operating income followed a similar pattern, rising from 166.83 crore in Mar'19 to 268.72 crore in Mar'25. The company's operating profit (PBDIT) also saw substantial growth, climbing from 11.06 crore in Mar'20 to 59.26 crore in Mar'25, with an operating profit margin that improved from 5.38% to 19.0% during the same period. Profit before tax surged from 9.00 crore in Mar'19 to 69.86 crore in Mar'25, while profit after tax rose from 7.22 crore to 55.36 crore, indicating a robust increase in profitability. The company's total assets grew from 146.95 crore in Mar'20 to 278.26 crore in Mar'25, with total liabilities also increasing from 146.95 crore to 278.26 crore. Cash flow from operating activities improved significantly, reaching 55.00 crore in Mar'25 compared to 11.00 crore in Mar'20. Overall, Jagsonpal Pharma has demonstrated strong financial growth and improved profitability over the years.

When is the next results date for Jagsonpal Pharma?

Jagsonpal Pharma will announce its results on 03 November 2025.

Jagsonpal Pharma will declare its results on 03 November 2025.

Is Jagsonpal Pharma overvalued or undervalued?

As of June 5, 2024, Jagsonpal Pharma is considered very expensive and overvalued with a PE ratio of 39.87, significantly higher than its peers, indicating that investors may be paying too much for its future growth potential despite a strong recent performance.

As of 5 June 2024, Jagsonpal Pharma's valuation grade has moved from expensive to very expensive, indicating a significant increase in perceived valuation. The company is currently considered overvalued. Key ratios include a PE ratio of 39.87, a Price to Book Value of 6.45, and an EV to EBITDA of 27.96, all of which are elevated compared to industry norms.<BR><BR>In comparison to peers, Jagsonpal Pharma's PE ratio is higher than Sun Pharma's 35.25 and significantly exceeds Cipla's 22.99, highlighting its premium valuation. While the company has shown strong returns over the past year, with a 71.87% increase compared to the Sensex's 7.58%, the current valuation metrics suggest that investors may be paying too much for future growth potential.

Who are the top shareholders of the Jagsonpal Pharma?

The top shareholders of Jagsonpal Pharma include Aresko Progressive Private Limited with 20.08%, followed by individual investors holding 20.94%, and Manish Gupta as the highest public shareholder at 2.49%. There are no pledged promoter holdings or mutual fund investments in the company.

The top shareholders of Jagsonpal Pharma include the promoters, who hold the majority of the shares. The promoter with the highest holding is Aresko Progressive Private Limited, which owns 20.08% of the company. Additionally, there are 11 Foreign Institutional Investors (FIIs) holding a combined 2.1% of the shares. The highest public shareholder is Manish Gupta, with a holding of 2.49%. Individual investors collectively hold 20.94% of the shares. There are no pledged promoter holdings, and no mutual funds are currently invested in the company.

Has Jagsonpal Pharma declared dividend?

Jagsonpal Pharmaceuticals Ltd has declared a 100% dividend, amounting to ₹5 per share, with an ex-date of September 6, 2024. The company has shown strong total returns over various periods, particularly impressive over the long term, despite a recent short-term decline.

Jagsonpal Pharmaceuticals Ltd has declared a 100% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 100%<BR>- Amount per share: 5<BR>- Ex-date: 06 Sep 24<BR><BR>Dividend Yield: 0.86%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -15.44%, with a dividend return of 0%, resulting in a total return of -15.44%.<BR><BR>Over the past year, the price return was 78.07%, the dividend return was 3.72%, leading to a total return of 81.79%.<BR><BR>In the last 2 years, the price return stood at 57.23%, with a dividend return of 3.24%, culminating in a total return of 60.47%.<BR><BR>For the 3-year period, the price return was 93.26%, the dividend return was 4.31%, resulting in a total return of 97.57%.<BR><BR>Over the past 4 years, the price return reached 361.1%, with a dividend return of 15.53%, leading to a total return of 376.63%.<BR><BR>In the 5-year period, the price return was an impressive 1943.42%, with a dividend return of 67.57%, resulting in a total return of 2010.99%.<BR><BR>Overall, Jagsonpal Pharmaceuticals Ltd has declared a significant dividend while demonstrating strong total returns over various periods, particularly notable in the longer-term performance. The company appears to be a solid investment with a consistent track record of returns, despite a recent decline in the short term.